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Abstract
Background: European guidelines recommend the use of ticagrelor versus clopidogrel in patients with ST elevation
myocardial infarction (STEMI). This recommendation is based on inconclusive results and subanalyses from clinical trials.
Few data are available on the effects of ticagrelor in a real-world population.
Methods: To compare the effects of ticagrelor and clopidogrel in a real-world STEMI population, we conducted a
pre-post case-control study examining all patients with STEMI included in the Cardio-STEMI Sanremo registry between
February 2011 and June 2013. Cases and controls were defined according to P2Y12 inhibitors, correcting the bias due
to lack of randomization by propensity score analysis. Ticagrelor was introduced in 2012 in both in-hospital and
pre-hospital settings independently of this study.
Results: Of the 416 patients enrolled in the Cardio-STEMI registry, 401 with a definite diagnosis of STEMI were included
in this study. One hundred forty-two patients received ticagrelor and 259 received clopidogrel. Regarding clinical
presentation and procedural data, those in the ticagrelor group had lower CRUSADE scores (23 [14–36] vs 27 [18–38];
p = 0.015] but a higher proportion of radial access (33% vs 14%; p < 0.001), percutaneous coronary intervention
(PCI; 92% vs 81 %; p = 0.002) and primary PCI ≤ 12 h (82% vs 66%; p = 0.001). The patients in the ticagrelor group had
a higher procedural success rate (100% vs. 96%; p = 0.044). There was no difference in Bleeding Academic Research
Consortium bleeding and in unadjusted incidence of hospital major adverse cardiovascular events (MACE; cardiac
death, myocardial infarction, or stroke) but there was a significant reduction in unadjusted cardiac hospital
death in the ticagrelor group (0.7% vs 5.4%; p = 0.024). After correcting for propensity score, hospital death
(p = 0.22) and hospital MACE (p = 0.96) did not differ in both groups. The unadjusted survival at 1 year after
STEMI was higher in the ticagrelor group (97.8% vs 87.8%; p = 0.024), and this result was confirmed by
propensity score analysis (hazard ratio = 0.29 [0.08–0.99]; p = 0.048).
Conclusions: In this real-word propensity score analysis, ticagrelor did not affect the risk of MACE during the
hospital phase, or the incidence of hospital bleeding in patients with STEMI. However, in this mono-centric
experience, ticagrelor resulted in improved 1-year survival, even after correction by propensity score.
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Background
Patients with ST elevation myocardial infarction (STEMI)
represent 32% of patients with acute coronary syndrome
(ACS), with in-hospital mortality ranging from 5% to 15%
according to geographic and baseline differences [1]. Each
year in the United States alone, hospital costs related to
acute myocardial infarction (AMI) are estimated to be as
high as US$11.5 billion [2].
Dual antiplatelet therapy (DAPT) is a cornerstone of
therapy for patients with STEMI. Clopidogrel has been
used extensively worldwide for more than a decade; more
recently, new antiplatelet agents, prasugrel and ticagrelor,
have been developed and tested clinically, resulting in
faster, more potent and consistent antiplatelet action [3–6].
Clopidogrel, a second-generation thienopyridine, is now
available as a low-cost generic drug, with a favourable cost-
effectiveness ratio. A drawback of clopidogrel is that as a
pro-drug, it needs liver metabolism to be activated. In
patients with STEMI, drug metabolism is hampered by
specific circulatory conditions, resulting in a delayed effect
of the drug compared with the time frame needed for
percutaneous coronary intervention (PCI) [7, 8]. Moreover,
this pathway is susceptible to genetic polymorphism, which
may lead to unexpected variations in drug activity.
Ticagrelor is a novel oral, reversible P2Y12 inhibitor
belonging to the cyclopentyltriazolopyrimidine class. It has
a plasma half-life of 12 h. It is an active drug with more
rapid onset and offset of action than clopidogrel, so that
inhibition and recovery of platelet function is faster [4, 9].
A large randomized controlled trial (RCT) showed the
superiority of ticagrelor compared with clopidogrel in
ACS in patients with STEMI and non-ST-segment eleva-
tion myocardial infarction (NSTEMI) [6]. This large RCT
led to a change in guideline recommendations in favour of
ticagrelor in patients with STEMI undergoing primary
PCI, largely reducing clopidogrel use in this setting. The
beneficial effects of ticagrelor were demonstrated to be
independent from the clinical presentation of STEMI,
because no interaction has been demonstrated in the
PLATO (Platelet Inhibition and Patient Outcomes) [8].
However, no specific randomized trial was designed to
detect the effect of ticagrelor in patients with STEMI,
leading to inconclusive and underpowered data [5, 10].
Although results from large real-world registries are
important to better understand the effectiveness, use and
outcomes of novel therapies [11–16], data on the benefits
of ticagrelor in a real-world population of patients with
STEMI are lacking. The sole large observational registry
about ticagrelor in STEMI population yielded results that
were in contrast with the PLATO trial, with no improve-
ment in ischaemic events and a higher rate of bleeding for
ticagrelor versus clopidogrel [17].
The safety and efficacy of drug-eluting stents (DESs)
based on the generation of the device and the duration of
DAPT have recently been examined. A recent meta-
analysis showed that patients treated with short DAPT
(<12 months) have similar survival (all-cause mortality
and cardiovascular mortality) than patients treated with
long DAPT (≥12 months). However, the RCTs collected in
the meta-analysis examined DAPT duration, not the type
of DAPT (ticagrelor vs clopidogrel), and the prevalence of
ACS was widely heterogeneous (32–77%). To date, we
have few data about the differences related to the type of
DAPT in a population of STEMI patients treated with
second-generation DESs.
We thus performed the present study to compare the
effect of ticagrelor and clopidogrel in a real-world popula-
tion of patients with STEMI.
Methods
A pre-post case-control study was performed using data
from the Cardio-STEMI Sanremo registry, a single-centre,
ongoing, observational cohort study conducted in Sanremo
Hospital, the hub for a population of 210,000 inhabitants,
with 2 spokes. Every adult patient (>18 years old) admitted
to the hub with a diagnosis of STEMI [18] was enrolled in
the registry.
Exclusion criteria were: type 4a or 5 AMI according to
the universal definition of myocardial infarction [19]; high
probability of being unavailable for follow-up visits
because of limited ability to cooperate or severe comor-
bidity with very short life expectancy.
For this study, all patients enrolled between February
2011 and June 2013 were examined. Ticagrelor became
available in addition to clopidogrel in May 2012, in both in-
hospital and pre-hospital settings. Since then, the choice
between the two drugs has been left to the cardiologist who
first makes the diagnosis of STEMI. Ticagrelor was intro-
duced into clinical practice independently from this obser-
vational study and in accordance with European guidelines
for the treatment of STEMI patients published in 2012
[20]. Patients were divided into the ticagrelor group and the
clopidogrel group according to the P2Y12 inhibitor
received. Local guidelines recommend the early administra-
tion of 2PY12 inhibitors, acetylsalicylic acid and unfractio-
nated heparin immediately after a STEMI diagnosis.
Therefore, in most patients presenting through the ambu-
lance service, 2PY12 inhibitors were administered during
the ambulance journey, usually after transmission of the
electrocardiogram report to the hub. Patients were treated
according to usual clinical practice at each institution, and
PCI was performed using standard techniques. All patients
received indication to continue DAPT for at least 1 year
after discharge, according to the current European and
American guidelines [20, 21]. Study endpoints were: (1)
TIMI flow grade before and after PCI [22] and ST
resolution 90 min after PCI; (2) the rate of hospital major
adverse cardiovascular events (MACE; cardiovascular
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death, AMI and stroke) and bleeding; (3) the 12-month
survival. MACE were defined according to the PLATO trial
criteria, with stroke defined as focal loss of neurologic
function caused by ischaemic or haemorrhagic events, with
symptoms lasting at least 24 h or leading to death [6].
Myocardial infarction (MI) was defined according to the
universal definition reported in the literature [19]. Bleeding
Academic Research Consortium (BARC) criteria were used
for bleeding assessment [23].
A paper-based case report form was prospectively
collected for each patient by the referring physician. All
the data were entered into an electronic database by 4
trained researchers, and the data entries were checked
periodically by a data manager. The validation of in-
hospital study outcomes was performed through the
periodic revision of medical documents. Follow-up was
performed with the support of a local health registry and a
telephone interview with the patient, family physician or
relatives [24]. Only mortality was inquired about during
post-discharge follow-up, because this endpoint can be
reliably and easily collected, and it is a surrogate for the
most severe sequelae such as re-infarction, stroke or
bleeding occurring during follow-up.
The Cardiology Department of Sanremo Hospital served
as the data analysis centre. The study was conducted in
accordance with the principles of the Helsinki Declaration
and received local ethical committee approval before
recruitment.
Statistical analysis
Baseline patient and procedural characteristics are
presented as means ± standard deviation, median (inter-
quartile range), or frequency (percentage) as appropriate.
The normal distribution of continuous variables in the
study was determined by Shapiro-Wilks and Kolmogorov-
Smirnov tests. Normally distributed continuous variables
were compared using the Student t test and those with
skewed distributions using the Mann-Whitney U test.
Categorical variables were compared using the χ2 test or
Fisher exact test. In-hospital nominal outcomes are
presented as proportions and odds ratios (OR) with
relative 95% confidence intervals (CI). We used Kaplan-
Meier curves for survival analysis and the log-rank test to
compare the treatment groups. With the aim of reducing
bias related to the lack of randomization, a propensity
score was calculated [25, 26] using a non-parsimonious,
multivariate, binary logistic regression model.
Variables presenting a p value ≤0.2 for the univariate
analysis and those judged to be of clinical importance,
biologically plausible or supported by previously published
data in the literature, were tested for inclusion in the
multivariable model building process. Variables with a
missing rate ≥ 5% were excluded.
Model discrimination was measured by the C statistic
and calibration by the Hosmer-Lemeshow goodness-of-fit
test [27]. The propensity score was used as a correction
factor in a binary logistic regression to calculate the
adjusted hospital outcomes and in a Cox regression
analysis to examine the adjusted 1-year survival. The Cox
regression results were expressed by hazard ratios (HR)
with 95% CIs. All tests were two-sided. A p value ≤0.05 was
considered statistically significant. Statistics were calculated
using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA).
Results
A total of 416 patients were enrolled in the Cardio-
STEMI Sanremo registry during the study period. Fifteen
patients (3.6%) were subsequently ruled out with condi-
tions mimicking MI, and were therefore excluded from
this study. The study flowchart is shown in Fig. 1. The
study population included 401 patients, 259 patients in
the clopidogrel group and 142 patients in the ticagrelor
group. From its introduction into clinical practice in May
2012, its use had peaked at 83% by the end of 2012. Data
on the adoption of ticagrelor in clinical practice are
reported in Fig. 2.
Demographic and baseline data are reported in Table 1.
Comparing the baseline data of the 2 groups, there were no
significant differences between ticagrelor and clopidogrel,
except for a lower proportion of patients aged over 75 years
(21% vs 32%, respectively; p = 0.037), with no difference in
median age.
In the ticagrelor group, all patients received the loading
dose, administered in 98% of cases before the cardiac
catheterization laboratory; in the clopidogrel group, 236
patients (91%) received the loading dose (42% >300 mg as
reported in Fig. 3), administered in 94% before the cardiac
catheterization laboratory.
With regard to clinical presentation and reperfusion
strategy, a lower CRUSADE score (23 [14–36] vs 27
[18–38]; p = 0.015], a higher rate of PCI (92% vs 80%;
p = 0.002) and primary PCI within 12 h (82% vs 66%;
p = 0.001) were found in the ticagrelor group compared
with the clopidogrel group. (Table 2). The laboratory tests
were similar between the 2 groups (Additional file 1).
Procedural data and times are reported in Table 3. The
only significant difference was a higher frequency of the
radial access approach for PCI in the ticagrelor group
(33% vs 14%; p < 0.001). For patients undergoing
primary PCI, the frequency of thrombus aspiration (45%
vs 37%; p = 0.22) and the use of glycoprotein (GP) IIb/
IIIa receptor antagonists (13% vs 17%; p = 0.41) were
comparable in the ticagrelor and clopidogrel groups.
With regard to the type of stent used, there were no
significant differences between the clopidogrel and tica-
grelor groups, although the use of bare metal stents was
nominally higher in the clopidogrel group (27% vs 15%).
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Fig. 1 Study flowchart. CABG coronary artery bypass grafting, DAPT dual antiplatelet treatment, ECG electrocardiogram, CI confidence interval,
NA not available
Fig. 2 Introduction of ticagrelor in clinical practice
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In each group, most of the DESs were second-generation
devices.
The system-related delay, patient-related delay and the
time intervals were not different between the 2 groups. Discharge therapy was not significantly different between
the ticagrelor and clopidogrel groups (Additional file 2).
Procedural success, defined either as TIMI 3 or TIMI
2–3 with stenosis <50% after primary PCI, was higher in
the ticagrelor group than in the clopidogrel group (99% vs
90%, p = 0.001; 100.0% vs. 96%, p = 0.044), whereas the
proportion of patients with ≥50% ST resolution (78% vs
78%; p = 0.879) or ≥70% ST resolution (60% vs 67%;
p = 0.294) was similar between the groups. Data on
procedural outcomes are reported in Table 4.
In the unadjusted analysis, there was no difference in
hospital MACE (cardiovascular death, non-fatal MI,
stroke) between the ticagrelor and clopidogrel groups
(4.9% vs 6.9%; p = 0.520; OR, 0.69 [95% CI, 0.28–1.70]).
However, the use of ticagrelor resulted in a significant
reduction of cardiovascular mortality (0.7% vs 5.4%;
p = 0.024; OR, 0.12 [95% CI, 0.02–0.95]). No difference
was found in new hospital non-fatal AMI (3.5% vs 1.2%,
Table 1 Baseline and demographic data. Data are expressed as






Age (years) 66 (56–73) 67 (56–67) 0.206
Age ≥ 75 years 21.8 (31) 32.0 (83) 0.037
Sex male 73.9 (105) 69.9 (81) 0.420
BMI (kg/m2)a 26 (24–30) 26 (24–29) 0.772
Hypertension 52.8 (75) 56.0 (145) 0.600
Dyslipidemia 36.6 (52) 39.0 (101) 0.668
Active smoke 45.8 (65) 37.8 (98) 0.137
Diabetes mellitus 22.5 (32) 18.5 (48) 0.362
Familiar of CAD 21.1 (30) 24.7 (64) 0.461
Previous stable angina 11.3 (16) 6.6 (17) 0.128
Previous unstable angina 3.5 (5) 4.6 (12) 0.797
Previous AMI 11.3 (16) 11.2 (29) 1.000
Previous PCI 7.0 (10) 9.3 (24) 0.574
Previous CABG 1.4 (2) 0.0 (0) 0.125
Previous CVA 4.9 (7) 7.3 (19) 0.403
PVD 16.2 (23) 11.2 (29) 0.164
Chronic kidney disease 7.0 (10) 4.6 (12) 0.361
COPD 8.5 (12) 8.9 (23) 1.000
Previous bleeding 0.7 (1) 3.9 (10) 0.106
Previous neoplasia 10.6 (15) 15.8 (41) 0.175
Italics: p value ≤0.05
BMI body mass index, CAD coronary artery disease, AMI acute myocardial
infarction, PCI percutaneous coronary intervention, CABG coronary artery
bypass grafting, CVA cerebrovascular accident, PVD peripheral vascular disease,
COPD chronic obstructive pulmonary disease








Fig. 3 Clopidogrel loading dose
Table 2 Clinical presentation and reperfusion strategy. Data are
expressed as percentage (frequency), median (IQR), or mean (SD)
Ticagrelor Clopidogrel p
Call to emergency service 43.0 (61/142) 41.3 (107/259) 0.75
Secondary transfer by
emergency service
40.8 (58/142) 40.3 (104/258) 0.92
Hub vs spoke 67.1 (94/140) 64.5 (167/259) 0.65
Anterior AMI 46.5 (66/142) 39.8 (103/259) 0.21
New LBBB at first EKG 2.3 (5/142) 3.5 (6/256) 0.53
Cardiac frequency (bpm) 75 (65–88) 77 (63–94) 0.28
Systolic blood pressure (mmHg) 140 (120–160) 140 (120–160) 0.76
Killip class ≥ 3 5.6 (8/142) 8.1 (21/259) 0.42
Cardiac arrest 2.1 (3/142) 3.1 (8/259) 0.75
LV ejection fraction (%) 46 (40–55) 45 (40–55) 0.83
GFR Cockroft Gault (mL/min/m2) 72 (55–90) 67 (52–86) 0.08
GFR MDRD (mL/min/m2) 76 ± 25 72 ± 23 0.09
GRACE-in-hospital mortality 139 (122–157) 141 (121–167) 0.32
GRACE 6-month mortality 106 (86–128) 106 (87–125) 0.96
TIMI risk score 3 (2–5) 4 (2–5) 0.18
CRUSADE 23 (14–36) 27 (18–38) 0.015
Thrombolysis 1.8 (4/142) 4.6 (12/259) 0.44
Coronary angiography 100.0 (142/142) 93.1 (241/259) 0.001
PCI 92.3 (131/142) 80.7 (209/259) 0.002
Primary PCI (≤12 h after
first medical contact)
82.4 (117/142) 66.4 (172/259) 0.001
IABP 0.7 (1/142) 3.1 (8/259) 0.17
Italics: p value ≤0.05
AMI acute myocardial infarction, LBBB left bundle branch block, EKG,
electrocardiogram, LV left ventricle, GFR glomerular filtration rate, MDRD
modification of diet in renal disease, GRACE global registry of acute coronary
events, TIMI thrombolysis in myocardial infarction, CRUSADE can rapid risk
stratification of unstable angina patients suppress adverse outcome with early
implementation of ACC/AHA Guidelines, PCI percutaneous coronary
intervention, IABP intra-aortic balloon pump
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p = 0.14) or in cerebrovascular accidents (0.4% vs 0.7%
vs 0.8%; p = 1.000) (Table 4). No significant difference
between the ticagrelor and clopidogrel groups was found
in stent thrombosis (1.4% vs 0.8%, p = 0.62) and infarct
size, estimated by the peak creatine kinase value (1347 vs
1372 UI/L, p = 0.77), or for left ventricular ejection
fraction (50% vs 48%, p = 0.55) before hospital discharge.
The causes of cardiovascular death are reported in
Additional file 3.
BARC bleeding was similar between the 2 groups; there
was no difference in BARC categories for BARC ≥2 and
BARC ≥3. The lowest median haemoglobin value (12.2 vs
12.2 g/dL; p = 0.8) and the difference between the highest
and lowest haemoglobin value during hospital stay (2.2 vs
2.1 g/dL; p = 0.9) were similar between the ticagrelor and
clopidogrel groups. The risk of transfusion and the
amount of packed red blood cell units did not show any
significant difference (Additional file 4).
In the Kaplan-Meier analysis, unadjusted 1-year survival
probability was higher in the ticagrelor group than in the
clopidogrel group (97.8% vs 87.8%; log-rank p = 0.024)
(Fig. 4), as was the probability of 1-year survival free from
Table 3 Procedural data in patients with STEMI and in primary
PCI. Data are expressed as percentage (frequency) or median (IQR)
Ticagrelor Clopidogrel p
Radial vs femoral 33.1 (47/142) 14.5 (35/241) <0.001
Left main 1.4 (2/142) 2.1 (5/241) 1.00
Multi-vessel CAD 36.6 (52/142) 36.5 (88/241) 1.00
Culprit vessel 0.19
RCA 38.7 (53/137) 38.9 (91/234)
CX 10.9 (15/137) 17.9 (42/234)
LAD 48.9 (67/137) 41.5 (97/234)
Other 1.5 (2/137) 1.7 (4/234)
Complete revascularization 58.0 (76/131) 56.9 (119/234) 0.91
Total contrast amount (mL) 200 (147–268) 203 (148–284) 0.89
Primary PCI
Multi-vessel CAD 35.9 (42/117) 34.9 (88/241) 0.90
Culprit vessel 0.44
RCA 38.8 (45/116) 39.0 (67/172)
CX 11.2 (13/116) 15.7 (27/172)
LAD 48.2 (56/116) 43.0 (74/172)
Others 1.8 (2/116) 2.3 (4/172)
TIMI flow pre-PCI 1 (0–3) 1 (0–3) 0.09
Reperfusion before PCI
(TIMI 3)
26.5 (31/117) 16.9 (29/172) 0.047
Reperfusion before PCI
(TIMI 2 o 3)
45.3 (53/117) 37.8 (65/172) 0.22
Type B2-C ACC/AHA lesion
classification
73.6 (81/110) 74.5 (117/155) 0.78
Thrombus aspiration 44.8 (52/116) 37.2 (64/172) 0.22
GPIIb/IIIa receptor antagonist 12.8 (15/117) 16.9 (29/172) 0.41
Stent type 0.15
BMS 14.7 (17/116) 27.1 (46/170)
First-generation DES 0.9 (1/116) 0.6 (1/170)
Second-generation DES 75.0 (86/116) 61.8 (104/170)
BMS and DES 2.6 (3/116) 2.4 (4/170)
No stent 7.8 (9/116) 8.8 (15/170)
Symptom onset to EKG
(hh:min)
1:25 (0:40–2:26) 1:19 (0:50–2:41) 0.84
EKG to door hub (hh:min) 1:26 (1:14–2:10) 1:21 (1:06–1:51) 0.25
Transfer time (hh:min) 0:42 (0:36–0:52) 0:38 (0:34–0:48) 0.11
DTB min (hh:min) 1:46 (1:35–2:37) 1:49 (1:34–2:30) 0.75
DTB ≤60 min 3.5 (4/114) 3.0 (5/166) 1.00
DTB ≤90 min 20.2 (23/114) 21.7 (36/166) 0.88
DTB ≤120 min 52.6 (60/114) 52.4 (87/166) 1.00
Total ischaemic time(hh:min) 3:50 (2:45–5:34) 3:30 (2:42–5:39) 0.37
Italics: p value ≤0.05
CAD coronary artery disease, RCA right coronary artery, CX circumflex coronary
artery, LAD left anterior descending, ACC/AHA American College of Cardiology/
American Heart Association, GPIIb/IIIa glycoprotein IIb/IIIa, PCI percutaneous
coronary intervention, TIMI thrombolysis in myocardial infarction, BMS bare metal
stent, DES drug-eluting stent, EKG electrocardiogram, DTB door to balloon
Table 4 Procedural and hospital outcomes. Data are expressed






Procedural outcomes (unadjusted analysis)
TIMI flow post-PCI 3 (3–3) 3 (3–3) 0.002
Procedural success (TIMI 3
and stenosis <50%)
99.0 (115/116) 89.9 (151/168) 0.001
Procedural success (TIMI
2–3 and stenosis <50%)
100.0 (116/116) 95.8 (161/168) 0.044
STR% 89 (50–100) 100 (50–100) 0.482
STR ≥ 50% 78.1 (82/105) 78.2 (122/156) 0.879
STR% ≥ 70% 60.0 (63/105) 66.7 (104/156) 0.294
Hospital outcomes (unadjusted analysis)
In-hospital all-cause death 0.7 (1) 5.4 (14) 0.024
In-hospital CV death 0.7 (1) 5.4 (14) 0.024
In-hospital non-fatal AMI 3.5 (5) 1.2 (3) 0.14
Ischaemic CVA 0.4 (1) 0.7 (1) 1.00
Total CVA (ischaemic or
haemorrhagic)
0.4 (1) 0.7 (1) 1.00
Hospital MACE 4.9 (7) 6.9 (18) 0.52
Definite stent thrombosis 1.4 (2) 0.8 (2) 0.62
Final LVEF [%] 50 (40–55) 48 (40–55) 0.55
CPK peak [UI/L] 1347 (535–2590) 1376 (677–2491) 0.77
Hospital stay [days] 4 (4–6) 5 (4–6) 0.84
Italics: p value ≤0.05
TIMI thrombolysis in myocardial infarction, STR ST resolution, CV
cardiovascular, AMI acute myocardial infarction, CVA cerebrovascular accidents,
LVEF left ventricular ejection fraction, CPK creatine phosphokinase
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cardiovascular death (97.8% vs 90.2%; log-rank p = 0.005)
(Additional file 5).
Propensity score analysis
A total of 21 interfering variables were included in the
propensity score and are reported in Additional file 6.
Candidate variables included sex, age, BMI, smoking,
diabetes, dyslipidemia, familiar history of coronary artery
disease, cerebrovascular accident (CVA), bleeding, previ-
ous AMI or PCI, glomerular filtration rate, TIMI risk
score, CRUSADE score, anterior AMI, first medical
contact through the ambulance service, admission to hub
vs spoke, left ventricular ejection fraction, Killip class III-
IV, radial access, primary PCI ≤12 h.
The propensity score was calculated for 368 patients
(missing for 33, 8.2%) and showed good discrimination
(area under the curve =0.695 [0.640–0.751]; p < 0.01) and
good calibration (p = 0.355). Using propensity score regres-
sion, there were no differences in mortality, ischaemic or
haemorrhagic events during the hospital stay. As showed in
Fig. 5, after adjusting for the propensity score, hospital
cardiovascular mortality (OR, 0.27 [95% CI, 0.03–2.19];
p = 0.218) and hospital MACEs (OR, 1.02 [95% CI,
0.38–2.79];], p = 0.963) were similar in the ticagrelor and
clopidogrel groups.
However, the survival analysis adjusted by propensity
score demonstrated that all-cause mortality at 1 year after
STEMI remained significantly lower for the ticagrelor
group (HR, 0.29 [0.08–0.99]; p = 0.048).
Fig. 4 Kaplan-Meier survival analysis for ticagrelor (red) vs clopidogrel (black) for 1 year of follow- up
Fig. 5 Forest plot for in-hospital major adverse cardiovascular events
(MACE), cardiovascular death and Bleeding Academic Research Consortium
(BARC) bleeding. Unadjusted (at the top) and propensity-adjusted
(at the bottom) odds ratio (OR) for in-hospital MACE, cardiovascular death
and BARC bleedings ≥2. CI confidence interval
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There were 6 crossovers from clopidogrel to ticagrelor
(3 for STEMI occurring on clopidogrel therapy, 3 for
unknown cause), and 17 crossovers from ticagrelor to
clopidogrel (4 for high bleeding risk or vitamin K antagon-
ist [VKA], 2 for dyspnoea, 2 for low patient compliance, 4
for low ischaemic risk after coronary angiography, 4 for
unknown cause). Seven of 401 patients were proposed for
elective coronary artery bypass graft (1.7%) during
hospitalization, 5 in the clopidogrel group and 2 in the
ticagrelor group. Ten patients were discharged without
DAPT for high bleeding risk or contemporary VKA therapy
(Fig. 1).
Discussion
In real-world populations of patients with STEMI admit-
ted to an Italian hospital, treatment with ticagrelor
reduced the mortality rate at 1 year compared with
clopidogrel, with a risk of mortality 3.4 times higher for
clopidogrel than for ticagrelor. This was confirmed when
propensity analysis was used to reduce the risk of bias
because of lack of randomization. Ticagrelor did not
reduce hospital MACE after propensity score correction,
and it did not affect hospital bleeding according to the
BARC classification.
The new 2PY12 inhibitors, ticagrelor and prasugrel, are
known to have more favourable pharmacologic proprieties
for ACS than clopidogrel. Because of more predictable
pharmacokinetics and a more potent and constant effect
with faster onset, there is strong rationale for their use in
patients with STEMI [4, 9]. However, despite promising
pharmacological data and European guidelines recommen-
dations to administer the new 2PY12 inhibitors in patients
with STEMI [28], there is still uncertainty about their real
clinical efficacy compared with the older and more widely
adopted clopidogrel.
The STEMI population differs from the larger ACS
population in several respects, because it is composed
of younger patients with less comorbidities and lower
procedural haemorrhage risk, but higher incidence of
hemodynamic instability at presentation. Moreover,
conditions affecting drug bioavailability, such as reduced
gastrointestinal absorption, vomiting and morphine ad-
ministration, can reduce the effect of P2Y12 more in
patients with STEMI than other ACS [8, 29]. In an RCT
directly comparing ticagrelor and clopidogrel, patients
with STEMI had a delayed onset of both these P2Y12
inhibitors [30]. A delayed onset of action for ticagrelor
was also confirmed in a small randomized trial measuring
platelet reactivity after a loading dose of ticagrelor and
prasugrel in patients with STEMI [9].
With no randomized trial focusing on the effect of
ticagrelor or prasugrel versus clopidogrel in a STEMI
population and the uncertainties about pharmacokinetics,
the source of evidence on the new 2PY12 inhibitors in the
STEMI population is still the subgroup analysis in the
PLATO and TRITON-TIMI 38 trials [10].
The TRITON-TIMI trial subgroup analysis showed that
prasugrel was superior to clopidogrel (300 mg loading
dose/75 mg maintenance dose) in 3534 patients with
STEMI undergoing primary or secondary PCI when
considering cardiovascular death, non-fatal MI, or non-
fatal stroke at 30 days (115 [6.5%] vs 166 [9.5%]; 0.68
[0.54–0.87]; p = 0.0017] and at 15 months (174 [10.0%] vs
216 [12.4%]; 0.79 [0.65–0.97]; p = 0.0221). A subanalysis
in the PLATO trial on 7544 patients with STEMI has
shown no superiority in MACE (cardiovascular death,
non-fatal MI and stroke) for ticagrelor versus clopidogrel
at 12 months follow-up, although there was a nominal
trend in favour of ticagrelor (HR, 0.87 [0.75–1.01];
p = 0.07). However, in this analysis, ticagrelor significantly
reduced secondary endpoints such as total mortality (HR
0.82; p = 0.05), MI (HR, 0.8; p = 0.03), and definite stent
thrombosis (HR 0.66; p = 0.03).
Because the PLATO and TRITON-TIMI 38 trials are
heterogeneous with regard to patient characteristics and
treatments, their results could not be compared. The
TRITON-TIMI 38 trial enrolled clopidogrel-naive patients
undergoing primary and secondary PCI, whereas in
PLATO almost 50% of patients were preloaded with open-
label clopidogrel (300 or 600 mg), reducing the benefit of
ticagrelor in the early phase of follow-up. Considering the
PLATO subgroup analysis, ticagrelor did not reduce the
primary endpoint at 12 months but conferred a survival
advantage after 30 days, and this may be the result of a
mechanism that differs from antiplatelet activity. Type 1
equilibrative nucleoside transporter (ENT1) protects
adenosine from intercellular metabolism. Inhibiting ENT1
increases the concentration and biological activity of adeno-
sine, particularly at sites of ischemia and tissue injury where
it is formed [31]. Furthermore, in patients with STEMI, the
beneficial effect of ticagrelor may be more pronounced in a
subpopulation of high-risk patients characterized by high
on-treatment platelet reactivity even after large loading
doses of clopidogrel [32]. In these patients, even a double
dose of clopidogrel did not reduce cardiovascular events
compared with the standard dose, as demonstrated by the
CURRENT-OASIS trial [33].
Despite the large number of patients included, PLATO
and TRITON-TIMI 38 were not designed specifically to
assess the effect of P2Y12 in patients with STEMI, and both
trials are underpowered to reach a definitive conclusion;
the low quality of this conclusion is summarized in the B
level of evidence in the European guidelines [28].
In the absence of high-quality RCTs, however, there is
increasing interest in prospective observational registries.
The Swiss ATACS registry analysed the effect of prasugrel
on a STEMI population, demonstrating that it is advanta-
geous over clopidogrel (in-hospital mortality 1.7% vs 4.4%)
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at the expense of an increased bleeding risk (significantly
superior for prasugrel on adjusted but not crude analysis)
[15]. Another Swiss observational study, the Swiss ACS
bleeding score, demonstrated that clopidogrel and prasu-
grel had similar safety profiles at 30 days (BARC 3, 4, 5 ad-
justed HR, 0.75 [0.42–136]) and at 1 year (BARC 3, 4, 5
adjusted HR, 0.67 [0.38–1.20]), without considering effi-
cacy [14]. The SCAAR registry from Sweden demon-
strated that ticagrelor increased survival and reduced
bleeding risk in selected patients with ACS at low risk of
bleeding [11]. Conversely, there is no European registry
on the effect of ticagrelor in the STEMI population. The
Greek GRAPE registry considered the clinical effect of
clopidogrel, prasugrel, and ticagrelor in the general ACS
population, hindering conclusions on the STEMI
population. The GRAPE study demonstrated that
ticagrelor does not reduce the rate of MACE at 1 year
(HR, 0.78 [0.54–1.12]), whereas the bleeding rate
increased (HR, 1.81 [1.55–2.10]) [16].
Our study is one of the few available registries on the
effect of ticagrelor in a STEMI population and is the first
to focus on the European setting. It has confirmed the
findings from the PLATO trial. Our study demonstrated
no benefit for ticagrelor with regard to cardiovascular
death, AMI and stroke during the hospital phase. The
risk reduction observed for in-hospital unadjusted car-
diovascular mortality was not confirmed after propensity
score analysis. This may be because of the use of a high
clopidogrel loading dose (over 42% patients ≥300 mg) in
the pre-hospital phase through the ambulance service.
These results are concordant with the PLATO trial,
where the beneficial effect of ticagrelor on MACE was
achieved only after 30 days.
In our data, ticagrelor did not increase the risk of
bleeding according to the BARC classification. This may
depend on the lower haemorrhagic risk of the STEMI
population compared with the general ACS population.
The low haemorrhagic risk could have reduced the rate of
clinically relevant bleeding even if the drug demonstrated
a larger antiplatelet effect. Both these findings are in
accordance with the PLATO subanalysis on STEMI.
A recent meta-analysis found a 20% reduced rate of
MACE in patients on the new P2Y12 compared with
clopidogrel [34], at the expense of a 50% increase in the
risk of stroke. This was not confirmed in our study,
where the proportions of MACE and stroke were similar
in the 2 groups.
The main result of the present study, a reduction in 1-
year mortality for ticagrelor, is concordant with the results
of the PLATO study and the substudy in the STEMI
population. In our registry, limited by the small sample
size, this finding may be the result of statistical chance;
however, it may also result from pharmacodynamic pro-
prieties of ticagrelor that are distinct from its antiplatelet
function, such as adenosine mimetic action [31]. More-
over, it may result from a favourable ratio between the
unavoidable haemorrhagic risk and protection from
ischaemic events. The observational registry by Park et al.
[17] on ticagrelor in a STEMI population yielded contrast-
ing results, showing that it did not reduce the risk of
ischaemic events but was associated with an increased risk
of bleeding compared with clopidogrel after controlling
for propensity score. That study was conducted in Korea,
thus it may lack external validity in Europe due to genetic
variations and difference in patient characteristics, such as
BMI or age. Furthermore, Park et al. considered only pa-
tients with STEMI undergoing PCI, excluding patients
with STEMI undergoing medical therapy, where the bene-
ficial effect of ticagrelor vs clopidogrel is increased [35].
In the present study, there was a 10% improvement in
the success rate of primary PCI in patients on ticagrelor,
with improvement in post-PCI TIMI 3 score (p = 0.001).
This result came from crude data, without randomization
or propensity score correction. Therefore, the better angio-
graphic results in patients treated with ticagrelor could be
secondary to chance. The PLATO angiographic substudy
[36] showed that neither coronary flow nor myocardial
perfusion demonstrated a difference with ticagrelor versus
clopidogrel. However, in this substudy, the time interval
between randomization and angiography or PCI was really
short, particularly in the STEMI patients. In our institution,
many patients were pretreated before arrival at the
catheterization laboratory and the time for the pharmaco-
logical effect was longer. This fact, associated with greater
platelet inhibition with ticagrelor, could have improved
angiographic outcomes. Ticagrelor is also known to inhibit
cell uptake of adenosine [31], and it could also be hypothe-
sized that ticagrelor might increase the concentration of ad-
enosine in the myocardium more than clopidogrel,
inducing hyperemia and vasodilation, which is inconsistent
with the results of the PLATO angiographic subgroup,
where there was no improvement in coronary flow after
percutaneous revascularization [36]. We should underline
that this finding came from crude analysis and it could be
biased by the lack of randomization or propensity score
correction. However, in our sample, as in the PLATO
angiographic subgroup, ticagrelor and clopidogrel achieved
a similar proportion of ST resolution after PCI, with no
effects on cardiac reperfusion.
Ticagrelor was discontinued in 2% of patients due to
dyspnoea, a previously reported complication [6]. Other pa-
tients were converted to clopidogrel because of compliance
problems, increased haemorrhagic risk or contemporary
VKA treatment. There was only one intra-hospital death in
the ticagrelor group (caused by cardiogenic shock), com-
pared with 14 intra-hospital deaths in the clopidogrel
group; this difference is relevant but it was not significant
after controlling for the propensity score.
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Limitations
This study has the limitations of a prospective case-control
study. There were some differences between baseline and
procedural data. Cases and controls were enrolled in differ-
ent time periods, and this may contribute to confounding
and to the different sizes of the study groups. However, we
used propensity scores to minimize the bias related to lack
of randomization, a strategy commonly used in other
studies based on similar prospective registries. Power may
be limited by sample size, however to our knowledge this
study is the largest real-world registry on ticagrelor in
Europe, even though the study was not powered for hard
endpoints. The use of radial access was lower than the
current standard and this issue could have had an unfavor-
able impact, increasing the bleeding risk in our sample.
However, the type of access was included in the propensity
score model in order to reduce the interference related to
the differences between ticagrelor and clopidogrel groups.
One further limitation is the lack of data collection on
MACE and bleeding after the hospital phase. This may
have influenced the perception of the favourable effects on
the rate of MACE, which may become apparent only after
30 days [6]. However, this choice is often used during
follow-up data collection within observational registries, as
mortality is more easily and reliably collected after dis-
charge, and it may be considered a surrogate outcome of
complications including MACE and bleeding. Although
the 2012 ESC guidelines recommended the use of ticagre-
lor or prasugrel in place of clopidogrel, in our institution
prasugrel was not introduced during the time window
examined in this study. This is mainly because prasugrel
should not be administered in patients older than 75 years,
with low body weight (≤60 kg) or with a history of previ-
ous CVA. So its introduction in our STEMI network,
particularly in the pre-hospital setting, was considered
difficult. We have no data on the duration of DAPT;
however, each patient received indication to continue
DAPT for at least 12 months after STEMI.
Conclusions
In this real-world single-centre experience, ticagrelor
resulted in improved survival at 1 year versus clopidogrel
in patients with STEMI, even after propensity score
correction. Ticagrelor did not reduce the composite
outcome of in hospital MACE, and it did not increase the
risk of in-hospital bleeding. Although these results con-
firm data from previous subanalysis in STEMI patients,
large RCTs are warranted to confirm the positive effect of
ticagrelor shown in this population.
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